Viewing Study NCT00139204



Ignite Creation Date: 2024-05-05 @ 11:47 AM
Last Modification Date: 2024-10-26 @ 9:14 AM
Study NCT ID: NCT00139204
Status: COMPLETED
Last Update Posted: 2009-11-01
First Post: 2005-08-29

Brief Title: Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine in Prostate Cancer Patients
Sponsor: Dana-Farber Cancer Institute
Organization: Dana-Farber Cancer Institute

Study Overview

Official Title: An Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine C11 MET in Prostate Cancer as Assessed by Positron Emission Tomography PET
Status: COMPLETED
Status Verified Date: 2009-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to better understand a new type of radiology test called positron emission tomography PET with carbon 11 methionine to determine which patients have a beneficial effect from anti-cancer therapy with the drug docetaxel
Detailed Description: In the week before the patients first dose of chemotherapy they will receive a C11 methionine PET scan which takes about 90 minutes C11 methionine is a radioactively labeled amino acid that is given to the patient intravenously

Eighteen to twenty days after the patients first dose of docetaxel chemotherapy they will have another C11 methionine PET scan which is identical to the first scan

At the end of three cycles of docetaxel chemotherapy about 2 and 12 months on study another C11 methionine PET scan will be done

The PET scans will show how well the tumor is taking up methionine

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None